Organization (Industry)
HALOZYME THERAPEUTICS, INC.
ClinicalTrials.gov lists HALOZYME THERAPEUTICS, INC. as lead sponsor of 33 trials. It has 2 active development programs and 25 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers HALOZYME THERAPEUTICS, INC.: 33 lead-sponsored trials and 3 legal-entity registrations.
Disease areas (32)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 11 |
| Insulin Resistance | 8 |
| Diabetes Mellitus, Type 1 | 7 |
| Dehydration | 5 |
| Pancreatic Neoplasms | 5 |
Showing 5 of 32 disease areas.
Trials by start year as sponsor or collaborator (17)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2023 | 1 |
| 2020 | 1 |
| 2019 | 2 |
| 2017 | 2 |
| 2016 | 4 |
| 2015 | 2 |
| 2014 | 1 |
| 2013 | 3 |
| 2012 | 1 |
Showing 10 of 17 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (2)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Testosterone Enanthate | Eunuchism | Phase 3 | 1 |
| Testosterone Enanthate | Hypogonadism | Phase 3 | 1 |
Approved assets (25)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Insulin LISPRO | 10 |
| rHuPH20 | 9 |
| Recombinant Human Hyaluronidase PH20 (rHuPH20) | 9 |
| Insulin Aspart | 6 |
| INSULIN GLULISINE | 4 |
Showing 5 of 25 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 33% hit target (n=6) | 67% on time (n=6) |
Journals published in (13)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Diabetes technology & therapeutics | 3 |
| Clinical therapeutics | 2 |
| Diabetes care | 2 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2 |
| Journal of pain and symptom management | 2 |
Showing 5 of 13 journals.
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 1,396,611,000 | 316,889,000 | 81,490,000 |
| 2024 | 1,015,324,000 | 444,091,000 | 79,048,000 |
| 2023 | 829,253,000 | 281,594,000 | 76,363,000 |
| 2022 | 660,116,000 | 202,129,000 | 66,607,000 |
| 2021 | 443,310,000 | 402,710,000 | 35,672,000 |
| 2020 | 267,594,000 | 129,085,000 | 34,236,000 |
| 2019 | 195,992,000 | -72,240,000 | 140,804,000 |
| 2018 | 151,862,000 | -80,330,000 | 150,252,000 |
| 2017 | 316,613,000 | 62,971,000 | 150,643,000 |
| 2016 | 146,691,000 | -103,023,000 | 150,842,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (22)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-11-12 | Debt financing | 1,470 | Sec extracted |
| 2025-11-12 | Debt financing | not disclosed | Sec extracted |
| 2025-11-06 | Private placement | not disclosed | Sec extracted |
| 2025-11-05 | Debt financing | not disclosed | Sec extracted |
| 2025-11-05 | Debt financing | not disclosed | Sec extracted |
Showing 5 of 22 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 1 |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (6)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University of Washington | Co sponsors trial with | 1 |
| Shire (Canada) | Co sponsors trial with | 1 |
| Merck & Co., Inc., Rahway, NJ, USA (United States) | Co sponsors trial with | 1 |
| Memorial Sloan Kettering Cancer Center | Co sponsors trial with | 1 |
| Pancreatic Cancer Research Team | Co sponsors trial with | 1 |
Showing 5 of 6 relationships.
Latest dated events (71)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2025-11-12 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-11-12 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-11-06 | Private placement | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-11-05 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-11-05 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 71 events.
Biomarker capability evidence (81)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 81 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.